Please login to the form below

CNS

This page shows the latest CNS news and features for those working in and with pharma, biotech and healthcare.

Boehringer’s IL-36-targeting drug tackles rare form of psoriasis

We are one of the first companies to focus on targeting IL-36 in dermatology,” said the privatey-held German company’s head of CNS and immunology R&D, Jan Poth.

Latest news

Roche’s rival to Bayer’s Vitrakvi gets speedy FDA review

CNS penetration could give edge over rival. The FDA has started a priority review of Roche’s entrectinib for NTRK fusion cancers, setting up a market clash with Bayer. ... set an important unmet need in ROS1, particularly in…CNS patients.”.
UniQure cleared to start Huntington gene therapy trial

pictured below), adding that the company is also hoping to apply its platform to other CNS diseases such as spinocerebellar ataxia type 3 (SCA3).
Chugai gains FDA breakthrough status for rare CNS treatment

Adds to company's BTD roll-call. The FDA has granted Breakthrough Therapy Designation to Chugai’s satralizumab, a treatment currently in phase 3 for the rare CNS disorders neuromyelitis optica ... NMOSD is a rare, lifelong, and debilitating autoimmune
Open Health merges with med comms services provider Peloton

The company says the deal allows it to better serve its US-based clients, along with boosting its science platform, thanks to Peloton’s expertise in rare disease, CNS, oncology and
Theranexus takes Alzheimer’s drug combo into clinic

Theranexus. The biotech’s platform is based on combining CNS drugs targeting neurons with a glial cell-modulating agent that it thinks can improve the response to the primary therapy, and

More from news
Approximately 4 fully matching, plus 163 partially matching documents found.

Latest Intelligence

China’s clinical trial shake-up

These reporting rules require sponsors to upload information such as endpoints and eligibility criteria to www.chinadrugtrials.org.cn.
Key considerations for disease- modifying Parkinson’s disease trials

By Dr Peter Schueler, Senior Vice President, Drug Development Services and Haichen Yang, Vice President, Global Therapeutic Lead, both at CNS, ICON plc.
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

The company is working on RNAi molecules which can work in CNS, something which would expand its therapeutic possibilities enormously, and hopes to have its first CNS-targetting candidate enter clinical
A quest for innovative solutions

PRISM has matured into an artery of new opportunities such as its collaboration on RADAR-CNS (Remote Assessment of Disease and Relapse - Central Nervous System), an initiative that aims to develop
The good, the bad and the ugly

Pfizer has large sales in CNS - $8.5bn in 2017. The majority come through Lyrica ($5bn). ... In Europe, a patent dispute over Lyrica became arguably the biggest CNS story in recent years.

More from intelligence
Approximately 0 fully matching, plus 41 partially matching documents found.

Latest appointments

Axovant poaches Allergan’s and Teva’s chief medical and science officers

development. “We have a wonderful opportunity to develop life-changing medicines for patients with CNS diseases.
Damien McDevitt moves from GSK to Acadia Pharmaceuticals

At Acadia, which focuses on the development and commercialisation of medicines for central nervous system (CNS) disorders, McDevitt will report to the company’s president and chief executive officer Steve Davis. ... This expertise, combined with his
Ron Menezes joins Almirall’s Aqua Pharmaceuticals

Menezes joins the group from Depomed Pharmaceuticals, where he served as vice president of sales and sales operations, pain and CNS.
emotive boosts its client services team

Joining as a senior account director, Andy Parry has 9 years’ experience in healthcare communications and has worked on global brands in CNS, infectious diseases, respiratory and rare disease.
Axon bolsters team with new PR Director hire

During her career, Smiddy has led local, regional and international programmes to support pharmaceutical products in numerous therapeutic fields including cardiology, immunology, CNS and oncology.

More from appointments
Approximately 0 fully matching, plus 25 partially matching documents found.

Latest from PMHub

Innovative approaches in the treatment of multiple sclerosis

Multiple Sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system (CNS), leading to progressive and permanent disability. ... In the central nervous system (CNS, which includes the brain, optic nerves and spinal cord),
Shionogi Ltd. appoints Star for UK launch

Their pipeline focuses on infectious disease, pain, CNS and oncology. Star were chosen as preferred partner on the basis of the company’s ability to provide the very best talent to
A fast-growing client services team at emotive.

Starting his career in Medical Education and then moving into healthcare advertising, Andy has worked on large global brands in CNS, infectious diseases, respiratory and rare diseases. ... Also with a Biomedical Science degree, Sabrina worked in
M3 announces further expansion into Europe and Latin America with the acquisition of Vidal Group

About M3:. M3 operates in Asia, the US and Europe with more than 4 million physician doctor members globally via M3.com, MDLinx, Medigate, medlive.cn, M3Medical and Doctors.net.uk.
New appointments announced across Research Partnership’s global offices

Marianne has over 15 years’ experience in healthcare marketing research. She has extensive experience in a variety of therapy areas including oncology, diabetes, autoimmune disorders, CNS, women’s health and cardiovascular